Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1308A plus lenvatinib in first-line advanced hepatocellular carcinoma
jRCT2061210033Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of quavonlimab + pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Objective response rate. Started Nov 2021; status: completed.
02
Drugs
quavonlimab + pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2061210033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210033.